Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer

CONCLUSIONS: Phosphoproteomic analysis may help elucidate the mechanisms of resistance to molecular-targeted therapies in lung cancer. Mutual phosphorylation of FAK and Src is involved in osimertinib resistance. Thus, FAK and Src inhibition may be novel treatment strategies for osimertinib-resistant NSCLC.PMID:38646155 | PMC:PMC11031815 | DOI:10.1016/j.jtocrr.2024.100668

Source: Clinical Lung Cancer - April 22, 2024 Category: Cancer & Oncology Authors: Takehiro Tozuka Rintaro Noro Keisuke Yoshida Satoshi Takahashi Mariko Hirao Kuniko Matsuda Yasuhiro Kato Shinji Nakamichi Susumu Takeuchi Masaru Matsumoto Akihiko Miyanaga Shinobu Kunugi Kazufumi Honda Jun Adachi Masahiro Seike Source Type: research